MAPT and Alzheimer disease: Plasma Aβ42/40 is a reliable marker of the neocortical Aβ burden, as validated by positron emission tomography (PET) in AD patients [9], whereas plasma p-tau181 correlates with Aβ and tau PET uptake [10].